Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the not-so-appetizing possibilities, we invite you to join us for a needed cuppa stimulation. Our choice today is green tea with ginger. Meanwhile, here is the latest menu of tidbits to help you on your way. We hope you conquer the world and have a wonderful day. And as always, please do stay in touch. …

When one of Rhode Island’s most-wanted fugitives was discovered last week to have been secretly working under an alias in the biotech industry, the reaction among many was shock, STAT says. How did he evade scrutiny for two decades? And how did the companies that hired him — at least one biotech on a full-time basis and at least two large drugmakers on a contractual basis — not vet him more thoroughly? But to an industry recruiter who spoke with Richard Graydon — the alias used by Ronald Fischer, a former doctor who was convicted of sexual assault and had spent two decades on the run — it wasn’t all that surprising. His stellar academic credentials, board certification, and years of experience leading teams that successfully developed cancer drugs made him an ideal candidate for top jobs. Much of his CV appears to have been fabricated, but it checked the right boxes.

A New Hampshire hospital is challenging a new Eli Lilly policy that requires certain hospitals to submit claims data when dispensing the company’s drugs under the federal 340B drug discount program, Bloomberg Law writes. The lawsuit filed by Mary Hitchcock Memorial Hospital alleges Lilly’s requirement imposes an illegal policy with “non-negotiable terms” and “retaliatory pricing penalties in order to extract commercially valuable data.” The hospital said it refused to comply with the company’s demands, which were announced in February. Earlier this month, Lilly began terminating discounts to dozens of hospitals.

Continue to STAT+ to read the full story…

​Read More

Published

on

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the not-so-appetizing possibilities, we invite you to join us for a needed cuppa stimulation. Our choice today is green tea with ginger. Meanwhile, here is the latest menu of tidbits to help you on your way. We hope you conquer the world and have a wonderful day. And as always, please do stay in touch. …

When one of Rhode Island’s most-wanted fugitives was discovered last week to have been secretly working under an alias in the biotech industry, the reaction among many was shock, STAT says. How did he evade scrutiny for two decades? And how did the companies that hired him — at least one biotech on a full-time basis and at least two large drugmakers on a contractual basis — not vet him more thoroughly? But to an industry recruiter who spoke with Richard Graydon — the alias used by Ronald Fischer, a former doctor who was convicted of sexual assault and had spent two decades on the run — it wasn’t all that surprising. His stellar academic credentials, board certification, and years of experience leading teams that successfully developed cancer drugs made him an ideal candidate for top jobs. Much of his CV appears to have been fabricated, but it checked the right boxes.

A New Hampshire hospital is challenging a new Eli Lilly policy that requires certain hospitals to submit claims data when dispensing the company’s drugs under the federal 340B drug discount program, Bloomberg Law writes. The lawsuit filed by Mary Hitchcock Memorial Hospital alleges Lilly’s requirement imposes an illegal policy with “non-negotiable terms” and “retaliatory pricing penalties in order to extract commercially valuable data.” The hospital said it refused to comply with the company’s demands, which were announced in February. Earlier this month, Lilly began terminating discounts to dozens of hospitals.

Continue to STAT+ to read the full story…

​Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read